Autoimmune Clinical Trials

229 recruitingLast updated: May 21, 2026

There are 229 actively recruiting autoimmune clinical trials across 37 countries. Studies span Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3, Phase 4. Top locations include Beijing, Beijing Municipality, China, Houston, Texas, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Autoimmune Trials at a Glance

229 actively recruiting trials for autoimmune are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Phase 2 with 40 trials, with the heaviest enrollment activity in Beijing, Houston, and New York. Lead sponsors running autoimmune studies include Tongji Hospital, Institute of Hematology & Blood Diseases Hospital, China, and Peking Union Medical College Hospital.

Browse autoimmune trials by phase

About Autoimmune Clinical Trials

Looking for clinical trials for Autoimmune? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Autoimmune trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Autoimmune clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 229 trials

Recruiting

Deciphering the Genetic Architecture of Autoimmune Diseases

Autoimmune Diseases
National Human Genome Research Institute (NHGRI)300 enrolled2 locationsNCT06948110
Recruiting

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

MelanomaRheumatoid ArthritisAnkylosing Spondylitis+10 more
M.D. Anderson Cancer Center125 enrolled1 locationNCT04751396
Recruiting
Phase 1

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.100 enrolled8 locationsNCT06680037
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Genetic DiseaseAutoimmune DiseasesNeurological Diseases or Conditions+1 more
Imagine Institute500 enrolled32 locationsNCT07040774
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting

The Mycophenolate Pregnancy Registry

Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
Genentech, Inc.500 enrolled1 locationNCT01733082
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 1Phase 2

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 2

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)354 enrolled2 locationsNCT02579967
Recruiting

Coagulopathy of Immunodermatologic Diseases

Autoimmune Bullous Dermatosis
University of Nebraska39 enrolled1 locationNCT06037187
Recruiting
Phase 2

A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease

Autoimmune EncephalitisAnti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
Arialys Australia Pty Ltd30 enrolled1 locationNCT07093333
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 2

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Autoimmune Encephalitis (AE)
University Hospital, Toulouse40 enrolled1 locationNCT07488117
Recruiting

Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS

Myelodysplastic SyndromesAplastic AnemiaAutoimmune Hemolytic Anemia+1 more
Institute of Hematology & Blood Diseases Hospital, China323 enrolled1 locationNCT07578675
Recruiting
Not Applicable

Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients

Autoimmune Hepatitis
Indiana University48 enrolled1 locationNCT06250309
Recruiting
Phase 2

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Autoimmune Lymphoproliferative Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)15 enrolled3 locationsNCT06730126
Recruiting
Not Applicable

Testimonials and Navigation in Rheumatology

Autoimmune DiseasesRheumatologic Disease
University of Alabama at Birmingham1,170 enrolled3 locationsNCT06469788